Provided are methods for producing afucosylated antibodies, the afucosylated antibodies and composition thereof and cells for producing antibodies. The method comprises introducing a nucleic acid encoding at least one modified enzyme of the fucosylation pathway to a host cell to produce the afucosylated antibody in the host cell. The afucosylated antibodies produced by the disclosed methods have increased ADCC activity and would not suppress their CDC and safety.

Disclosed is a method for producing 2′-fucosyllactose from a recombinant Corynebacterium sp. introduced with fucosyltransferase derived from Pseudopedobacter saltans. The recombinant Corynebacterium sp. microorganism introduced with fucosyltransferase derived from Pseudopedobacter saltans is capable of producing 2′-fucosyllactose at a high concentration, high yield and high productivity.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of proteins and glycoproteins. The methods, systems, components, and compositions may be utilized for incorporating non-standard amino acids (nsAAs) into cell-free synthesized proteins and glycosylating or otherwise modifying the cell-free synthesized proteins in vitro. The nsAAs of the cell-free synthesized protein may be modified via glycosylation or other modification.

It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

Compositions and methods are provided for producing 2fucosyliaciose and L-fucose from recombinant microorganisms.

The present disclosure relates to a method of obtaining a cell where fucosylation pathways are modified, leading to production of partially fucosylated and non-fucosylated protein products, specifically antibodies from the cell. The present disclosure employs the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. The method of the present disclosure targets the Fut8 gene and GMD gene in a cell. Such products are used in developing therapeutics and biomarkers, and in diagnosis and prognosis of diseases.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of proteins and glycoproteins. The methods, systems, components, and compositions may be utilized for incorporating non-standard amino acids (nsAAs) into cell-free synthesized proteins and glycosylating or otherwise modifying the cell-free synthesized proteins in vitro. The nsAAs of the cell-free synthesized protein may be modified via glycosylation or other modification.

Disclosed are a recombinant Corynebacterium glutamicum (C. glutamicum) for producing fucosyllactose which is transformed to express -1,2-fucosyltransferase, GDP-D-mannose-4,6-dehydratase (Gmd), GDP-L-fucose synthase (WcaG) and lactose permease (LacY), wherein the Corynebacterium glutamicum has phosphomannomutase and GTP-mannose-1-phosphate guanylyltransferase, and a method for producing fucosyllactose using the same. According to the recombinant Corynebacterium glutamicum and the method for producing fucosyllactose according to the present invention, with use of a GRAS Corynebacterium glutamicum strain, which is safer than conventional Escherichia coli, 2-fucosyllactose can be produced at a high concentration while overcoming drawbacks of conventional methods associated with industrial inapplicability resulting from low production concentrations.

Provided is a method of producing 2-fucosyllactose including culturing in a medium supplemented with lactose a recombinant Corynebacterium glutamicum transformed to express -1,2-fucosyltransferase, transformed to express GDP-D-mannose-4,6-dehydratase, transformed to express GDP-L-fucose synthase, and transformed to express lactose permease, wherein the recombinant Corynebacterium glutamicum has phosphomannomutase and GTP-mannose-1-phosphate guanylyltransferase.